BioNotebook: 3 IPOs launch, 2 file; AMAG 4Q earnings; Repros FDA update

On their first day as public companies, Egalet broke even, Eleven Biotherapeutics gained 8.5% and Revance Therapeutics closed 67.8% above its initial public offering price on 6 February.